Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

August 1, 2026

Conditions

HIV I InfectionCardiovascular Risk FactorLipid Metabolism Disorders

Interventions

DRUG

Doravirine 100 Mg

Doravirine 100 Mg orally dail

Trial Locations (2)

University of Texas Southwestern Medical Center, Dallas

University of Texas Southwestern, Dallas

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER